Hormonal
Dual and tri-agonists targeting GLP-1, GIP, and Glucagon receptors provide superior metabolic homeostasis and cardiovascular benefits compared to mono-agonists by leveraging cooperative hormonal signaling.
Current GLP-1 treatments are effective, but newer dual and triple hormone therapies (targeting GLP-1, GIP, and Glucagon receptors) offer broader metabolic and cardiovascular benefits. These are available as weekly or daily injections, and in some cases, oral formulations, addressing the burden of daily dosing.
a logical and rational approach is the use of the dual and triagonism of GCPC to achieve complete metabolic homeostasis... demonstrated their safety, efficacy, and beneficial effects on the CV system.
Why this rating
Review of clinical trials and animal models; strong mechanistic evidence but relies on ongoing/phase trials for some agents.
Source
Novel Therapies for Cardiometabolic Disease: Recent Findings in Studies with Hormone Peptide-Derived G Protein Coupled Receptor Agonists
Elena Jiménez-Martí et al. · Nutrients · 2022
DOI 10.3390/nu14183775
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →